Skip to main content

Abinitio Bio

Abinitio Bio provides an AI-native operating platform for drug development and manufacturing, integrating developability assessment, process development, scale-up, and production into a single GxP-compliant system. The platform streamlines quality and regulatory reporting through evidence assembly and drafting, with built-in review gates, version history, and accountable approvals to ensure every decision is documented and traceable.

san francisco, United States · HQ
Founded 20265500+ followers
  • Artificial Intelligence
  • Biotechnology
  • Drug Discovery & Therapeutics
  • Healthcare Technology
  • Software Only
Updated 16 days ago

Funding

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Drug development and manufacturing teams face fragmented workflows across developability assessment, process development, scale-up, and production, leading to slow decision-making, inconsistent data, and costly delays. Regulatory compliance requires rigorous documentation and approval trails, but existing tools lack integrated, GxP-native controls, forcing teams to manually assemble evidence and manage version histories across disconnected systems.

Solution

Abinitio Bio provides an AI-native operating platform that unifies the entire drug development and manufacturing lifecycle, from candidate assessment through regulatory approval. The platform enables teams to assess developability, accelerate manufacturing process development, and streamline quality and regulatory reporting within a single system. It embeds GxP-native controls directly into the workflow, including review gates, version history, and accountable approvals, ensuring every decision is documented and traceable. The platform supports evidence assembly and drafting for regulatory submissions, reducing manual effort and improving accuracy. By covering the full spectrum from developability to manufacturing to quality, Abinitio Bio helps teams move faster while maintaining compliance and data integrity.

Target Audience

Primary customers are biopharmaceutical companies, CDMOs, and drug development teams that need to accelerate manufacturing process development while maintaining GxP compliance and regulatory readiness.

Features

  • AI-native operating layer that spans developability, process development, scale-up, manufacturing, quality, and regulatory functions
  • Built-in GxP-native controls with review gates, version history, and accountable approvals for compliance-ready workflows
  • Evidence assembly and drafting tools for quality and regulatory reporting
  • Integrated platform covering the full lifecycle from candidate readiness assessment to production and approval
  • Decision review and outcome ownership features that document rationale and maintain audit trails
This profile is AI-generated and may contain inaccuracies.